Palladia Tablets for Dogs (Toceranib Phosphate) 10mg, 30 tablets

Targeted Mast Cell Tumor Treatment for Dogs

Product Description

PALLADIA is a prescription oral cancer therapy authorized by the FDA for dogs diagnosed with returning skin mast cell tumors graded II or III under the Patnaik system, regardless of whether the condition has spread to the lymph nodes. The active ingredient, toceranib phosphate, works by focusing on the pathways that help tumors grow. It also helps cut off the blood supply that cancer cells need to survive. When used under a veterinarian’s guidance, this targeted treatment can lead to a measurable response in tumor control.

Benefits

• Targeted Cancer Therapy: Selectively inhibits receptor tyrosine kinases involved in tumor growth and angiogenesis in canine mast cell tumors.
• Dual Mechanism Action: Helps slow the growth of tumor cells while also limiting the formation of new blood vessels that feed the tumor.
• Proven Clinical Response: In controlled studies, it showed a much higher response rate compared to a placebo.
• Oral Administration: Comes in a tablet form that is typically given every other day, as directed by a licensed veterinarian.
• Adjustable Dosing Protocol: Allows dose reductions or temporary interruptions to help manage treatment-related adverse effects.

Variants

• 10 mg tablets
• 15 mg tablets
• 50 mg tablets

Ingredients

Composition Table

How to Use

Recommended-Dosage Chart

Initial recommended dose is 3.25 mg/kg orally every other day. Dose adjustments may be required.

Dosage & Administration Instructions

• Prescription Only: Under federal regulations, this medication may only be administered by a licensed veterinarian or provided with a veterinarian’s prescription or authorization.
• Initial Dose: Give 3.25 mg per kg of body weight by mouth every other day, or exactly as your veterinarian instructs.
• Dose Adjustments: If side effects occur, your vet may lower the dose by 0.5 mg per kg or pause treatment for a period of time.
• Do Not Split: Do not cut or break the tablets. They need to stay intact to keep the protective coating effective.
• Food Flexibility: May be administered with or without food according to veterinary recommendation.

Disclaimer: This dosage information is provided by the manufacturer. Always consult your veterinarian before administering or adjusting any supplement for your pet.

Additional Information

Precautions

• Breeding Restriction: Do not use in breeding dogs or in pregnant or lactating bitches.
• Vascular Risk: This medication can affect blood vessels and may lead to swelling or blood clots. If this happens, treatment should be stopped right away.
• GI Monitoring: If there are signs of stomach ulcers or severe bleeding during treatment, the medication should be discontinued.
• Laboratory Monitoring: Regular checkups with your veterinarian are important. Blood tests will be needed to keep an eye on neutrophils, albumin, creatinine, and hematocrit levels.
• CYP3A4 Interaction: Use extra care when giving this drug alongside strong CYP3A4 inhibitors, as they can raise the levels of toceranib in the body.

Possible Side Effects

• Gastrointestinal Effects: Diarrhea, vomiting, anorexia, and blood in stool are commonly reported reactions.
• Weight Loss: Significant body weight reduction has been observed during treatment phases.
• Neutropenia Risk: Decreased neutrophil counts may occur and require dose modification.
• Lameness Episodes: Dose-related lameness and musculoskeletal discomfort have been reported.
• GI Perforation: Rare but serious gastrointestinal perforations and hemorrhage have occurred.

Storage Information

• Controlled Temperature: Store at 20° to 25° C or 68° to 77° F.
• Secure Storage: Keep tablets in a secure location out of reach of children.
• Original Packaging: Keep tablets in the original container to maintain integrity and safety.

Shipping & Return

We offer ground, express, priority, and international delivery; see our shipping policy for details.

For return instructions or product concerns, please refer to our detailed refund policy.

Prescription items are NON-RETURNABLE and NON-REFUNDABLE.

Frequently Asked Questions

Q1: What is PALLADIA used for in dogs?

Ans: PALLADIA is indicated for the treatment of recurrent Patnaik grade II or III cutaneous mast cell tumors in dogs, with or without regional lymph node involvement. It is prescribed by veterinarians as part of a cancer treatment plan when measurable disease is present after surgery.

Q2: How does PALLADIA work against mast cell tumors?

Ans: PALLADIA contains toceranib phosphate, a receptor tyrosine kinase inhibitor that blocks signaling pathways involved in tumor cell growth and angiogenesis. It inhibits targets such as KIT, VEGFR2, and PDGFR, helping reduce tumor proliferation and blood vessel formation, supporting cancer progression.

Q3: How often should PALLADIA be given to dogs?

Ans: The initial suggested dosage is 3.25 milligrams per kilogram of the dog’s body weight, given by mouth on an every other day schedule. Dose reductions or temporary treatment interruptions may be required depending on laboratory findings or adverse reactions, as determined through regular veterinary monitoring.

Q4: What are the most common side effects of PALLADIA?

Ans: Commonly reported side effects include diarrhea, vomiting, decreased appetite, lethargy, lameness, weight loss, and blood in the stool. Laboratory abnormalities such as neutropenia and hypoalbuminemia have also been observed. Veterinary monitoring is essential during treatment.

Q5: Is PALLADIA safe for pregnant or breeding dogs?

Ans: PALLADIA should not be used in breeding dogs or in pregnant or lactating bitches. Because it inhibits angiogenesis, it may harm developing fetuses and is expected to cause adverse effects during pregnancy. Use only under direct veterinary supervision.